SYNTHORX
Summary
Synthorx is a clinical-stage biotechnology company focused on prolonging and improving the lives of people with cancer and autoimmune disorders.
Deals Overview
Total Deals1
Valued Deals1
Total Value£ 1.90 B
Avg. Deal Size£ 1.90 B
Senior Management
Laura Shawver
Chairman and CEO
Enoch Kariuki
Investors Relations Director
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
All rights reserved. Copyright © 2025 Datasite